Elevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy

BMC Pulmonary Medicine

Volumn 11, Issue , 2011, Pages

  Cheng, Shih Lung ^a,b,c   Wang, Hao Chien ^c   Cheng, Shih Jung ^c   Yu, Chong Jen ^c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b YUAN ZE UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

chronic obstructive pulmonary disease; Inhaled corticosteroids; Placenta growth factor

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; C REACTIVE PROTEIN; FLUTICASONE; PLACENTAL GROWTH FACTOR; BIOLOGICAL MARKER; GLUCOCORTICOID; PLACENTA PROTEIN;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PREVALENCE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; THORAX RADIOGRAPHY; BLOOD; CHEMICALLY INDUCED DISORDER; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR;

ADMINISTRATION, INHALATION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PREGNANCY PROTEINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 80053346677     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-11-46     Document Type: Article

References (44)

1. Hancox RJ, Poulton R, Ely M, et al. Global lung health; the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J 2010, 35:27-33. 10.1183/09031936.00072909, 20044459.
2. Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction accumulation of neutrophils in the lung of cigarette smokers. Am Rev Respir Dis 1983, 128:833-838.
3. Kanazawa H, Kurihana N, Hirata K, et al. The role of free radicals and neutrophil elastase in development of pulmonary emphysema. Intern Med 1992, 31:857-860. 10.2169/internalmedicine.31.857, 1333306.
4. Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005, 294:2712-2719. 10.1001/jama.294.21.2712, 16333006.
5. Farr BM, Bartlett CLR, Wadsworth J, et al. Risk factors for community- acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group. Respir Med 2000, 94:954-963. 10.1053/rmed.2000.0865, 11059948.
6. Restrepo MI, Mortensen EM, Pugh JA, et al. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006, 28:346-351. 10.1183/09031936.06.00131905, 16611653.
7. Holguin F, Folch E, Redd SC, et al. Comorbidity and mortality in COPD- related hospitalization in the United States, 1971 to 2001. Chest 2005, 128:2005-2011. 10.1378/chest.128.4.2005, 16236848.
8. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:74-81. 10.1183/09031936.03.00031402, 12570112.
9. Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbation on deterioration of health status in COPD. Eur Respir J 2004, 23:698-702. 10.1183/09031936.04.00121404, 15176682.
10. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. The Lancet 2003, 361:449-456.
11. Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-55. 10.1164/rccm.200703-456SO, 17507545.
12. Van Andel AE, Reisner C, Menjoge SS, Witek TJ. Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995. Chest 1999, 115:703-707. 10.1378/chest.115.3.703, 10084479.
13. Jackevicius CA, Chapman KR. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: a survey. Ann Pharmacother 1997, 31:160-164.
14. Niewoehner DE, Erbland ML, Deupree RH, et al. Department of Veterans Affairs Cooperative Study Group. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999, 340:1941-1947. 10.1056/NEJM199906243402502, 10379017.
15. Calverley PM, Anderson JA, Celli B, et al. TOUCH investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-798. 10.1056/NEJMoa063070, 17314337, TOUCH investigators.
16. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:; 144-149.
17. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, . INSPIRE Investigators The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19-26. INSPIRE Investigators.
18. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med 2010, 16:118-122. 10.1097/MCP.0b013e328334c085, 2908947, 19926996.
19. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009, 169:219-229. 10.1001/archinternmed.2008.550, 19204211.
20. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2009, 180:741-750. 10.1164/rccm.200904-0492OC, 19644045.
21. Sin DD, Tashkin D, Xuekui Z, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. The Lancet 2009, 374:712-719.
22. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009, 69:549-565. 10.2165/00003495-200969050-00004, 19368417.
23. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease: Results of a 6-Month Randomized Clinical Trial. Drugs 2008, 68:1975-2000. 10.2165/00003495-200868140-00004, 18778120.
24. DiPalma T, Tucci M, Russo G, et al. The placenta growth factor gene of the mouse. Mamm Genome 1996, 7:6-12. 10.1007/s003359900003, 8903720.
25. Torry DS, Wang HS, Wang TH, et al. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998, 179:1539-1544. 10.1016/S0002-9378(98)70021-3, 9855593.
26. Tsao PN, Su YN, Li H, et al. Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema. Am J Respir Crit Care Med 2004, 505-11. 15: 169:.
27. Cheng SL, Wang HC, Yu CJ, et al. Prevention of elastase-induced emphysema in placenta growth factor knock-out mice. Respir Res 2009, 10:115. 10.1186/1465-9921-10-115, 2789728, 19930612.
28. Cheng SL, Wang HC, Yu CJ, Yang PC. Increased expression of placenta growth factor in COPD. Thorax 2008, 63:500-506. 10.1136/thx.2007.087155, 2571977, 18202163.
29. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 26:2407-2416.
30. Yano K, Okada Y, Beldi G, et al. Elevated levels of placental growth factor represent an adaptive host response in sepsis. J Exp Med 2008, 205:2623-2631. 10.1084/jem.20080398, 2571936, 18852292.
31. Daniels JM, Schoorl M, Snijders D, et al. Procalcitonin versus C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2011,
32. Antoniu SA. Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease. Biomarkers 2010, 15:97-103. 10.3109/13547500903311902, 19929747.
33. Jeffery P. Anti-inflammatory effects of inhaled corticosteroids in chronic obstructive pulmonary disease: similarities and differences to asthma. Expect Opin Investig Drugs 2005, 14:619-632.
34. Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:736-743. 10.1164/rccm.200508-1321OC, 16424444.
35. Ozol D, Aysan T, Solak ZA, Mogulkoc N, Veral A, Sebik F. The effect of inhaled corticosteroids on bronchoalveolar lagave cells and IL-8 levels in stable COPD patients. Respir Med 2005, 99(12):1494-1500. 10.1016/j.rmed.2005.04.025, 15946834.
36. Strandberg K, Blidberg K, Sahlander K, Palmberg L, Larsson K. Effect of formoterol and budesonide on chemokine release, chemokine receptor expression and chemotaxis in human neutrophils. Pulm Pharmacol Ther 2010, 23(4):316-323. 10.1016/j.pupt.2010.03.004, 20307681.
37. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991, 88:9267-9271. 10.1073/pnas.88.20.9267, 52695, 1924389.
38. Maglione D, Guerriero V, Viglietto G, et al. Two alternative mRNA coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 1993, 31. 8: 925:.
39. Ziche M, Maglione D, Ribatti D, et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 1997, 76:517-531.
40. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007, 176:162-166. 10.1164/rccm.200611-1630OC, 17400730.
41. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010, 104:246-252. 10.1016/j.rmed.2009.10.002, 19879745.
42. Geerlings S, Hoepelman A. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999, 26:259-265. 10.1111/j.1574-695X.1999.tb01397.x, 10575137.
43. Parappil A, Depczynski B, Collett P, Marks GB. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology 2010, 15:918-922. 10.1111/j.1440-1843.2010.01781.x, 20546185.
44. Wieshammer S, Dreyhaupt J, Basler B. A link between impaired lung function and increased cardiac stress. Respiration 2010, 79:355-362. 10.1159/000265751, 20016119.